Search­ing for a few great drugs, Bridge­Bio bags $135M to back a fresh slate of R&D bets

Bridge­Bio is all about shots on goal.

The last time I wrote a sto­ry about the com­pa­ny in April, CEO Neil Ku­mar had just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.